Continuous infusion device and medical system
Patent Information
- Application Number
- JP2024510000
- Authority / Receiving Office
- JP · JP
- Patent Type
- Applications
- Filing Date
- 2024-08-15
- Publication Date
- 2024-12-04
- Estimated Expiration
- Not applicable · inactive patent
AI Technical Summary
Conventional continuous administration devices lack the ability to confirm their operational state from outside the body, leading to potential health risks due to malfunction or excessive substance release.
Incorporation of a notification unit within the device that alerts external detection systems when internal pressure exceeds a predetermined threshold, allowing for external monitoring of the device's functioning.
Enables immediate detection of device malfunctions, preventing adverse health effects and ensuring sustained and controlled substance release, thereby expanding therapeutic options.
Smart Images

Figure 2023181995000001 
Figure 2023181995000002
Abstract
Description
Continuous infusion device and medical system
[0001] The present invention relates to a continuous administration device that is placed in a living body and continuously administers a substance to be administered, such as a medicinal solution, and a medical system including the device.
[0002] Patent Document 1 discloses an osmotic delivery device, which is a sustained administration device that is implanted in a living body and sustainably releases a drug to be administered over a long period of time.
[0003] The device of Patent Document 1 generally comprises a hollow container (main body), a piston (stopper) slidably held within the container, an osmotic engine (pressing section) that serves as a driving source for pressing the piston, a semipermeable membrane (liquid-permeable section) located at the base end of the container and allowing liquid components in body fluid (extracellular fluid) to pass through the osmotic engine, and a delivery orifice (release section) located at the distal end of the container and releasing a drug pressed by the piston. The container is divided into two spaces by the piston: a drug-containing space (second space) located at the distal end of the container across the piston, and an osmotic agent-containing space (first space) located at the proximal end of the container on the opposite side of the piston from the second space. The device is configured to utilize the principle of osmotic pressure to swell the osmotic agent with the liquid components in the body fluid that have permeated the semipermeable membrane, and slide the piston toward the distal end as the internal pressure of the first space increases due to the swelling of the osmotic agent, releasing the drug contained in the second space into the living body.
[0004] JP 2017-57212 A
[0005] The device described in Patent Document 1 is a device that is placed in a living body and releases a substance to be administered over a certain period of time. Therefore, if a malfunction occurs in the device and the substance is not administered properly, it may cause health problems for the patient. In particular, drugs that achieve a certain therapeutic effect through continuous administration are difficult to use because malfunction of the device may cause serious health problems for the patient. Furthermore, if the internal pressure within the device increases abnormally as the stopper stops sliding, it may lead to an overdose (burst) of the substance to be administered.
[0006] Thus, in a continuous administration device, it is important to immediately check from outside the body whether or not the device function has stopped due to an abnormal increase in internal pressure within the lumen, etc. However, conventional continuous administration devices, including those described in the patent documents, have no way of checking the operating state from outside the body after being placed in the body.
[0007] At least one embodiment of the present invention has been made in consideration of the above-mentioned circumstances, and specifically aims to provide a continuous administration device that can be placed in a living body and whose operating state can be confirmed from outside the living body, and a medical system equipped with the device.
[0008] The continuous administration device of this embodiment comprises a main body having an inner cavity, a stopper body that can slide liquid-tightly within the inner cavity, a pressing section that is positioned upstream of the stopper body in the inner cavity and presses the stopper body downstream, an administered substance that is contained downstream of the stopper body in the inner cavity and released into the living body by the stopper body sliding downstream, and a release section that is positioned at the tip of the main body and releases the administered substance pressed by the stopper body into the living body, and is a continuous administration device that is placed within the living body for the sustained release of the administered substance, and comprises a notification section that notifies the outside of the stopped state of the stopper body when the internal pressure of the inner cavity exceeds a predetermined threshold due to the stopper body stopping movement.
[0009] The medical system according to this embodiment includes the continuous administration apparatus and an external device that includes a detection unit that detects the notification operation of the notification unit and is placed outside the living body.
[0010] According to at least one embodiment of the present invention, the operating state of a continuous infusion device placed in a living body can be confirmed from outside the living body. This makes it possible to avoid the risk of losing the administration effect of the administered substance due to the cessation of sustained release, or serious health damage due to a burst of the administered substance. Therefore, even drugs that cause serious side effects when overdosed can be administered without concern, thereby expanding the range of treatment options.
[0011] FIG. 1 is a functional block diagram of a medical system according to a first embodiment. FIG. 2 is a schematic cross-sectional diagram of a continuous administration device according to the first embodiment. FIG. 3 is a partially enlarged cross-sectional diagram of the vicinity of the base end of a continuous administration device according to the first embodiment. FIG. 4 is a functional block diagram of a medical system according to a second embodiment. FIG. 5 is a schematic cross-sectional diagram of a continuous administration device according to the second embodiment. FIG. 6 is a partially enlarged cross-sectional diagram of the vicinity of the base end of a continuous administration device according to the second embodiment. FIG. 7 is a functional block diagram of a medical system according to a third embodiment. FIG. 8 is a schematic cross-sectional diagram of a continuous administration device according to the third embodiment. FIG. 9 is a partially enlarged cross-sectional diagram of the vicinity of the base end of a continuous administration device according to the third embodiment. FIG. 10 is a partially enlarged cross-sectional diagram showing a modified example of a continuous administration device according to the third embodiment.
[0012] Hereinafter, embodiments of the present invention will be described in detail with reference to the drawings. The embodiments shown here are merely examples for embodying the technical concept of the present invention and are not intended to limit the present invention. Furthermore, all other embodiments, examples, and operational techniques that can be conceived by those skilled in the art without departing from the spirit of the present invention are included within the scope and spirit of the present invention, as well as within the scope of the claims and their equivalents.
[0013] Furthermore, for the convenience of illustration and ease of understanding, the drawings attached to this specification may be represented schematically with the scale, aspect ratio, shape, etc. appropriately changed from the actual product, but these are merely examples and do not limit the interpretation of the present invention.
[0014] Furthermore, in the following description, when ordinal numbers such as "first" and "second" are used, unless otherwise specified, they are used for convenience and do not stipulate any particular order.
[0015] In the continuous administration devices according to the first to third embodiments described below, the "distal side (downstream side)" refers to the side where the release section is located and where the substance X to be administered is administered, and the "proximal side (upstream side)" refers to the side opposite the distal side where the liquid permeable section is located and where the liquid in the living body enters. For example, in Figure 2, the distal side is on the right side in the drawing, and the proximal side is on the left side in the drawing.
[0016] First Embodiment A medical system 1A according to a first embodiment will be described with reference to FIGS. 1 to 3 as needed.
[0017] As shown in FIG. 1, the medical system 1A includes a continuous administration device 100A that is placed in a living body and that continuously administers (sustainedly releases) an administration substance X, such as a drug, into the living body, and an external device 200A that is placed outside the living body and that can detect a notification operation issued from the continuous administration device 100A and notify an external communication destination 300.
[0018] The medical system 1A has a function of notifying the outside when a predetermined malfunction occurs in the continuous administration device 100A placed in a living body. In detail, the medical system 1A performs a predetermined notification operation when the internal pressure in the lumen 11A exceeds a predetermined pressure due to the stopper body 40A being driven, in the continuous administration device 100A placed in a living body, detects the notification operation by an external device 200A placed outside the living body, and notifies a predetermined communication destination 300.
[0019] <Continuous Administration Device> The continuous administration device 100A is placed in a biological lumen (blood vessels, trachea, intestines, etc.), subcutaneously, or in biological tissue such as muscle, bone, or organ to slowly release the substance X to be administered into a living body, and can release the substance X under predetermined administration conditions (administration conditions such as administration period and dosage). The continuous administration device 100A can slowly release the substance X over a long period of time (at least several weeks to several months, or even several years).
[0020] The substance X administered from the continuous administration device 100A is a fluid composition that can be sustainedly released from the device to produce a predetermined effect in the target living body. For example, the substance X is a pharmaceutical (liquid) intended to treat a predetermined disease. The pharmaceutical includes drugs. Drugs can be any physiologically or pharmacologically active substance, particularly those known to be delivered to the human or animal body. Drugs include, but are not limited to, drugs that act on peripheral nerves, adrenergic receptors, cholinergic receptors, skeletal muscle, the cardiovascular system, smooth muscle, the vascular system, synaptic sites, neurotransmitter junctions, endocrine and hormonal systems, the immune system, the reproductive system, the skeletal system, the local hormonal system, the digestive and excretory systems, the histamine system, or the central nervous system. Drugs also include, but are not limited to, drugs used to treat infectious diseases, chronic pain, diabetes, autoimmune diseases, endocrine disorders, metabolic disorders, and rheumatic diseases. Additionally, drugs include, but are not limited to, peptides, proteins, polypeptides (e.g., enzymes, hormones, cytokines), nucleic acids, oligonucleotides, viruses, viral vectors, plasmids, nucleoproteins, polysaccharides, glycoproteins, lipoproteins, cells, steroids, analgesics, local anesthetics, antibiotic agents, anti-inflammatory corticosteroids, ophthalmic agents, other small molecules of pharmaceutical use, or synthetic analogs of these species, and mixtures thereof.
[0021] 2 or 3, the continuous administration device 100A generally comprises a main body 10A, a liquid-permeable portion 20A, a pressing portion 30A, a stopper 40A, and a release portion 50A. The continuous administration device 100A also comprises a notification portion 60A that performs a predetermined notification operation to the outside when the internal pressure in the lumen 11A or the pressing portion 30A reaches a predetermined pressure.
[0022] The main body 10A has an inner cavity 11A and is composed of a hollow tubular member that constitutes the housing of the continuous administration device 100A. The liquid permeable portion 20A, the pressing portion 30A, the stopper 40A, and the release portion 50A are arranged in this order from the base end to the tip end of the main body 10A.
[0023] The main body 10A has a first space Y1 and a second space Y2, separated by the stopper 40A. The first space Y1 is a space defined by the liquid permeable portion 20A and the stopper 40A (the space between the mounting end of the liquid permeable portion 20A in the main body 10A and the base end of the stopper 40A), and is a space in which the pressing portion 30A is housed. The second space Y2 is a space defined by the stopper 40A and the release portion 50A (the space between the base end of the stopper 40A and the base end of the release portion 50A), and is a space in which the stopper 40A and the substance X to be administered are housed. The second space Y2 also constitutes a sliding region for the stopper 40A.
[0024] The first space Y1 and the second space Y2 expand or contract as the stopper 40A slides before and after the continuous administration device 100A is driven. That is, when the continuous administration device 100A starts to drive, the first space Y1 gradually expands as the stopper 40A slides downstream due to the pressing unit 30A. Furthermore, when the continuous administration device 100A starts to drive, the second space Y2 gradually contracts as the stopper 40A slides downstream due to the pressing unit 30A.
[0025] In order to maintain the accuracy of the release of the substance X by the sliding of the stopper 40A, the main body 10A must prevent at least the lumen 11A in the sliding region of the stopper 40A from collapsing due to buckling or the like, thereby deforming the shape of the lumen 11A (the cross-sectional shape intersecting the axial direction) and impeding the sliding of the stopper 40A. Examples of materials that can be used to construct the main body 10A include resin materials that are non-invasive or minimally invasive to living bodies and are known in the medical field (such as acrylonitrile polymers, halogenated polymers, polyimide, polysulfone, polycarbonate, polyethylene, polypropylene, polyvinyl chloride-acrylic acid copolymer, polycarbonate-acrylonitrile-butadiene-styrene, and polystyrene), metal materials (such as stainless steel, titanium, nickel, aluminum, vanadium, platinum, tantalum, gold, and alloys thereof, as well as gold-plated ferroalloys, platinum-plated ferroalloys, cobalt-chromium alloys, and titanium nitride-coated stainless steel).
[0026] The liquid-permeable portion 20A is disposed on the proximal end side of the main body portion 10A, and separates the living body from the interior of the continuous administration device 100A while allowing only the liquid components contained in the body fluid in the living body to pass through. The liquid-permeable portion 20A is made of a member having a solid-liquid separation function that allows only the water content in the body fluid to pass through.
[0027] The liquid-permeable portion 20A may be, for example, a semipermeable membrane made of a material such as a plasticized cellulose-based material, a polymethyl methacrylate (PMMA) reinforced with hydroxylethyl methacrylate (HEMA), or an elastomer material such as polyurethanes, polyamides, polyether-polyamide copolymers, or thermoplastic copolyesters, or a mixture thereof.
[0028] The pressing portion 30A is located downstream of the liquid permeable portion 20A within the main body 10A and presses the plug 40A downstream. The pressing portion 30A is an osmotic pressure engine that swells and expands due to moisture that has permeated the liquid permeable portion 20A using the principle of osmotic pressure. The pressing portion 30A gradually swells due to moisture that has permeated the liquid permeable portion 20A, and the swelling causes an increase in internal pressure within the first space Y1, resulting in a pressing action that slides the plug 40A downstream.
[0029] The constituent materials and size of the pressing unit 30A can be appropriately determined so that the pressing speed of the stopper 40A (i.e., the swelling speed of the pressing unit 30A) corresponds to the conditions of use (such as the sustained release period of the substance X to be administered and the dosage per unit time). The sustained release period and dosage of the continuous administration device 100A can be adjusted by changing the composition of the osmotic engine that constitutes the pressing unit 30A and the shape, such as the water absorption rate, water absorption rate, and thickness, of the semipermeable membrane that constitutes the liquid permeable unit 20A.
[0030] The osmotic engine constituting the pressing unit 30A contains an osmotic agent ZA containing a hydrophilic polymer, an osmotic substance, or a mixture thereof. If the osmotic substance is a non-electrolyte, the osmotic agent ZA may further contain an electrolyte. Furthermore, the pressing unit 30A may be configured to continuously press at least the stopper 40A downstream, and may be configured as a mechanical system using a drive source other than an osmotic engine (e.g., a motor). The solubility, dissolution rate, swelling ratio, and osmotic pressure of the solution of the osmotic agent ZA, as well as the drive speed of the mechanical drive source, can be adjusted as desired.
[0031] The stopper 40A has a columnar base 41A extending in the longitudinal direction of the main body 10A and an annular ridge-like protrusion 42A protruding from the radial outer periphery of the base 41A. The stopper 40A is pressed by the pressing portion 30A to move downstream and push the substance X contained in the second space Y2 toward the release portion 50A. The stopper 40A is located downstream of the pressing portion 30A within the main body 10A, with its outer circumferential surface in liquid-tight contact with the inner circumferential surface of the lumen 11A of the main body 10A and slidably disposed within the lumen 11A.
[0032] A plurality of protrusions 42A are provided on the outer surface of base 41A, and the apex protruding most outwardly abuts against the inner circumferential surface of lumen 11A of main body 10A. Protrusion 42A forms a seal with the inner circumferential surface of lumen 11A to prevent substance X from leaking upstream of stopper 40A.
[0033] The number and location of the protrusions 42A are not particularly limited. The plug 40A may also be configured without the protrusions 42A, i.e., the outer circumferential surface of the base 41A may be in direct contact with the inner circumferential surface of the lumen 11A to provide a liquid-tight seal. This allows for adjustment of the frictional force between the plug 40A and the inner circumferential surface of the main body 10A, enabling stable sliding.
[0034] The plug 40A is made of a flexible material that maintains close contact (liquid-tightness) with the inner surface of the lumen 11A of the main body 10A. The flexible material is preferably an elastic material. Examples of elastic materials include various rubber materials (especially vulcanized ones) such as natural rubber, isoprene rubber, butyl rubber, chloroprene rubber, nitrile-butadiene rubber, styrene-butadiene rubber, and silicone rubber; styrene-based elastomers; hydrogenated styrene-based elastomers; and mixtures of these styrene-based elastomers with polyolefins such as polyethylene, polypropylene, polybutene, and α-olefin copolymers; oils such as liquid paraffin and process oil; and powdered inorganic materials such as talc, cast, and mica. Furthermore, polyvinyl chloride-based elastomers, olefin-based elastomers, polyester-based elastomers, polyamide-based elastomers, polyurethane-based elastomers, and mixtures thereof can be used as the constituent material. As the constituent material, diene rubber, styrene elastomer, etc., can be used, particularly from the viewpoint of having elastic properties and being capable of gamma ray sterilization, electron beam sterilization, and high-pressure steam sterilization. Note that the plug 40A only needs to be configured to slide liquid-tightly within the lumen 11A. Therefore, the base 41A and protruding portion 42A of the plug 40A may be configured from a flexible or elastic material. Alternatively, for example, only the protruding portion 42A that contacts the lumen 11A may be configured from an elastic material, while the base 41A may be configured from a hard material that does not have elasticity. Furthermore, the surface of the plug 40A may be coated with a coating that provides properties such as slipperiness, water repellency, and corrosion resistance.
[0035] The release section 50A is disposed at the distal end of the main body 10A and releases the substance X pushed out by the stopper 40A into the living body. The release section 50A has a through-hole penetrating a columnar member having a predetermined thickness along the axial direction to efficiently administer the substance X into the living body. When the release section 50A has multiple through-holes, the substance X can be dispersed within the living body without concentrating in one place. The shape, size, and number of through-holes in the release section 50A can be determined appropriately taking into account the properties of the substance X and the ease of diffusion of the substance X at the placement site of the continuous administration device 100A. The shape of the through-hole is not limited to a linear shape and may be, for example, a spiral shape. Alternatively, the through-hole may penetrate axially to the center of the release section 50A and then circumferentially through the main body 10A to the outside of the living body in a substantially V-shaped configuration.
[0036] As shown in FIG. 3 , the notification unit 60A performs a notification operation to notify the outside that an abnormality has occurred when the movement of the stopper 40A stops due to clogging of the discharge unit 50A or poor sliding of the stopper 40A, causing the internal pressure of the lumen 11A and the pressing unit 30A to exceed a predetermined threshold A. The notification unit 60A includes a power supply unit 61A that is driven in response to an increase in internal pressure within the lumen 11A, and a notification operation unit 62A that is driven by the drive voltage from the power supply unit 61A to perform a predetermined notification operation. To prevent short circuits due to the intrusion of liquid, etc., the notification unit 60A has a main body, a housing 63A, made of a liquid-impermeable material and disposed in the liquid-permeable unit 20A. The contact portion with the pressing unit 30A is made of a liquid-impermeable membrane member 64A that can transmit the increase in internal pressure within the lumen 11A to the power supply unit 61A, specifically, to the piezoelectric element 611A described below. In this way, the liquid-passing portion 60A is sealed by the housing 63A and the membrane member 64A, and is configured so that as the internal pressure of the inner cavity 11A increases, the increase in pressure of the pressing portion 30A due to the increase in internal pressure of the inner cavity 11A is transmitted to the piezoelectric body 611A via the membrane member 64A.
[0037] The power supply unit 61A has a piezoelectric body 611A made of a piezoelectric ceramic material and a pair of electrodes 612A, and is configured as a known piezoelectric element that generates a drive voltage from the internal pressure of the pressing unit 30A caused by the increase in internal pressure when the internal pressure in the lumen 11A exceeds a threshold A. When the movement of the plug 40A stops due to some malfunction and the internal pressure in the lumen 11A exceeds the threshold A, this internal pressure fluctuation is applied to the piezoelectric body 611A, and a voltage is generated by the piezoelectric effect. The power supply unit 61A supplies (applies) the generated voltage to the notification operation unit 62A as a drive voltage.
[0038] The "threshold A" can be set to a pressure value that is at least higher than the internal pressure in the lumen 11A when the stopper body 40A is operating normally, and lower than the pressure at which a burst of the administered substance X may occur due to an increase in internal pressure associated with the stopping of the stopper body 40A.
[0039] The notification operation unit 62A performs a predetermined notification operation and outputs notification information to the outside. The notification operation unit 62A is configured by a device that is driven by a drive voltage applied from the power supply unit 61A and can perform the predetermined notification operation.
[0040] The "notification operation" is an operation to notify the outside (outside the living body) that the drive of the plug 40A has stopped and the pressure in the lumen 11A has exceeded the threshold A, i.e., that an abnormality has occurred in the continuous administration device 100A. The notification operation unit 62A outputs the physical event that has occurred as a result of the notification operation to the outside as notification information. The notification operation unit 62A can be configured with a vibrator that is driven by a drive voltage applied from the power supply unit 61A and generates vibrations at a predetermined period. In addition to vibrations, notification operations also include operations that generate physical events such as heat, magnetic fields, sound, light, radio waves, and sound waves.
[0041] In this way, when the movement of the stopper body 40A stops due to some malfunction, the internal pressure in the lumen 11A increases as the stopper body stops moving, and the internal pressure exceeds the threshold A, the power supply unit 61A is activated to generate a drive voltage, and this drive voltage is applied to the notification operation unit 62A to perform a notification operation and notify the outside. The person to be notified (for example, a medical professional such as a doctor) can learn that an abnormality has occurred in the continuous administration device 100A via the external device 200A.
[0042] <External Device> The external device 200A is placed outside the living body as shown in Fig. 1. The external device 200A detects notification information from the notification unit 60A of the continuous administration device 100A and notifies the communication destination 300 that an abnormality has occurred in the continuous administration device 100A. The external device 200A is configured to include a detection unit 210A that detects a notification operation, and a communication processing unit 220A that notifies the communication destination 300 that the detection unit 210A has detected the notification operation.
[0043] The "communication destination" is a device owned or managed by a notification recipient, such as an administrator who manages the continuous administration device 100A or a patient in whom the continuous administration device 100A is placed. Examples of devices that can be the communication destination 300 include mobile terminals (smartphones, tablet terminals, mobile phones, etc.), external terminals such as PCs (including external management servers, etc.), and alarm devices with a predetermined alarm function (sound output devices with a sound generation function such as a buzzer or voice, and display devices such as alarm lamps and display devices with a lighting / flashing function and a character display function). However, the device that can be the communication destination 300 is not limited to the exemplified devices, and may be any device that can notify the notification recipient of an abnormality in the continuous administration device 100A.
[0044] The detection unit 210A is configured with a device capable of detecting notification information generated by the notification operation of the notification unit 60A. The detection unit 210A detects the notification information from the notification unit 60A and outputs the detection result to the communication processing unit 220A. If the notification information from the notification unit 60A is "vibration," the detection unit 210A can be configured with a vibration sensor capable of detecting displacement of the surface of the living body resulting from this vibration.
[0045] The communication processing unit 220A generates an abnormality notification signal based on the detection result from the detection unit 210A and transmits it to the communication destination 300. The communication processing unit 220A can be configured as a network interface that controls wireless communication with other devices via a communication network in accordance with a predetermined protocol. The communication processing unit 220A only needs to have a function that enables communication with the communication destination 300, such as short-range wireless communication with a communication distance of several centimeters to several tens of meters, such as Bluetooth (registered trademark) or Wi-Fi, or wireless communication using a carrier line network provided by a telecommunications carrier.
[0046] If the external device 200A has a function that can notify the notification recipient of an abnormality in the continuous administration device 100A without performing communication processing, such as a sound output device or display device, the communication processing unit 220A can be omitted. In this case, the external device 200A can notify the notification recipient of an abnormality in the continuous administration device 100A by using the detection unit 210A to detect the notification operation of the notification unit 60A and performing a predetermined notification operation (sound, light output, character display, etc.) based on the detection result of the detection unit 210A.
[0047] Furthermore, the medical system 1A is configured to detect notification information from the continuous administration device 100A using the external device 200A and confirm whether or not there is an abnormality in the continuous administration device 100A. However, if the notification information from the continuous administration device 100A is an event that can be confirmed by the person to be notified, the abnormality in the continuous administration device 100A can also be confirmed without using the external device 200A. For example, if the notification information from the continuous administration device 100A is a "sound," the person to be notified can learn of the abnormality in the continuous administration device 100A by hearing the specific sound (notification sound) that serves as the notification information.
[0048] In the medical system 1A according to the first embodiment described above, the continuous administration device 100A is filled with the substance X to be administered to the administration target, and then appropriately introduced into the living body by a percutaneous or surgical technique, etc. The external device 200A is placed at a position where a notification action issued from the continuous administration device 100A outside the living body can be detected, for example, on the surface of the living body near the placement position of the continuous administration device 100A.
[0049] In the continuous administration device 100A, it is assumed that the movement of the stopper 40A has stopped due to some malfunction. At that time, when the internal pressure in the lumen 11A exceeds a threshold A due to the stopper 40A's movement, the notification unit 60A applies a pressure exceeding the threshold A to the power supply unit 61A, generating a drive voltage. The notification unit 60A drives the notification operation unit 62A with the drive voltage generated by the power supply unit 61A to perform a predetermined notification operation.
[0050] When notification information is output by the notification operation of the notification unit 60A, the external device 200A detects this notification information with the detection unit 210A and transmits an abnormality notification signal to the communication destination 300 (for example, a mobile terminal carried by the person to be notified) via the communication processing unit 220A. This allows the person to be notified to immediately confirm the abnormality of the continuous administration device 100A. Therefore, when a malfunction occurs in the continuous administration device 100A, the person to be notified can respond quickly even if they are in a location away from the patient in whom the continuous administration device 100A is placed.
[0051] Second Embodiment Next, a medical system 1B according to a second embodiment will be described with reference to FIGS. 4 to 6 as needed.
[0052] In the medical system 1B according to the second embodiment, components having the same functions as those in the first embodiment are denoted by the same or related reference numerals, and detailed descriptions thereof are omitted, and no particular mention is made of them. The configuration, members, and method of use may be the same as those in the first embodiment.
[0053] 4 and 5, the medical system 1B is composed of a continuous administration device 100B and an external device 200B. The continuous administration device 100B also includes a main body 10B, a liquid-permeable portion 20B, a pressing portion 30B, a stopper 40B, a releasing portion 50B, and a notifying portion 60B.
[0054] As shown in Figures 4 and 5, the medical system 1B according to the second embodiment differs from the notification unit 60A of the first embodiment mainly in the configuration of the notification unit 60B. The pressing unit 30B is configured with an osmotic pressure engine that uses an osmotic agent ZB containing an electrolyte as a conductor required to drive the notification unit 60B. When the internal pressure in the lumen 11B increases and the stopper 40B stops moving, the stopper 40B prevents the expansion of the first space Y1 downstream, causing the osmotic agent ZB to flow upstream and into the notification unit 60B.
[0055] 5 or 6, the notification unit 60B includes a housing 61B serving as the main body, a liquid passage 62B provided in the housing 61B for the osmotic agent ZB flowing in from the pressing unit 30B, a blocking unit 63B that normally blocks the liquid passage 62B and opens the liquid passage 62B by the pressure of the pressing unit 30B caused by the increase in internal pressure when the internal pressure in the lumen 11B exceeds a predetermined threshold B, a power supply unit 64B that becomes energized by the osmotic agent ZB flowing in from the liquid passage 62B to generate a drive voltage, and a notification operation unit 65B that performs a predetermined notification operation when the drive voltage is applied from the power supply unit 64B. The notification unit 60B is arranged on the tip side of the liquid permeable unit 20B so that a portion of the osmotic agent ZB from the pressing unit 30B can flow in.
[0056] Like threshold value A, "threshold value B" can be set to a pressure value that is at least higher than the internal pressure in lumen 11B when stopper body 40B is operating normally, and lower than the pressure at which a burst of the administered substance X may occur due to an increase in internal pressure associated with the stopping of movement of stopper body 40B.
[0057] The housing 61B is made of a liquid-impermeable material to prevent short circuits in the power supply unit 64B and the notification operation unit 65B. The housing 61B is disposed at the tip side of the liquid permeable unit 20B so that the osmotic agent ZB can flow in. The liquid-passing unit 60B is sealed by a blocking unit 63B provided in the housing 61B and the liquid-passing port 62B.
[0058] The liquid passage 62B is formed on the tip side of the housing 61B facing the pressing unit 30B so that the osmotic agent ZB can flow in. The liquid passage 62B is normally blocked by the blocking unit 63B, and when the internal pressure in the lumen 11B exceeds the threshold B, that is, when an abnormality occurs in the continuous administration device 100B, the blockage by the blocking unit 63B is released. This opens the liquid passage 62B, allowing the osmotic agent ZB to flow in.
[0059] The blocking portion 63B is composed of a member that can release the blocked state of the liquid passage port 62B when the internal pressure in the lumen 11B exceeds a threshold value B, and blocks the liquid passage port 62B during normal operation to prevent the osmotic agent ZB and moisture that has permeated the liquid permeable portion 20B from flowing into the housing 61B. When an abnormality occurs and the internal pressure in the lumen 11B exceeds the threshold value B, the blocking portion 63B releases the blockage of the liquid passage port 62B.
[0060] The blocking portion 63B can be configured as a check valve, a membrane member, or the like that has the function of opening the liquid passage port 62B when the internal pressure in the lumen 11B exceeds the threshold value B. If the blocking portion 63B is configured as a check valve, the valve element that closes the liquid passage port 62B moves away from (or opens) the liquid passage port 62B due to the pressure when the internal pressure in the lumen 11B exceeds the threshold value B, thereby opening the liquid passage port 62B. If the blocking portion 63B is configured as a membrane member, when the internal pressure in the lumen 11B exceeds the threshold value B, at least a portion of the membrane member breaks due to the pressing force of the osmotic agent ZB, thereby opening the liquid passage port 62B.
[0061] The power supply unit 64B generates and supplies the drive voltage required to drive the notification operation unit 65B. The power supply unit 64B is composed of a battery 642B connected to a pair of electrodes 641B spaced apart within the housing 61B to ensure an insulating distance. The power supply unit 64B uses the electrolyte contained in the osmotic agent ZB as a conductor, and becomes electrically conductive when the electrode 641B is immersed in the osmotic agent ZB that flows in through the liquid passage 62B. Therefore, the power supply unit 64B does not operate unless the internal pressure of the lumen 11B exceeds the threshold B and the blockage of the liquid passage 62B by the blocking portion 63B is released. The power supply unit 64B supplies (applies) the drive voltage generated by the conduction between the osmotic agent ZB that flows in through the liquid passage 62B and the electrode 641B to the notification operation unit 65B. The type of battery constituting the power supply unit 64B is not particularly limited as long as it can be accommodated within the housing 61B and is capable of generating a drive voltage sufficient to drive the notification operation unit 65B.
[0062] The notification operation unit 65B is driven by a drive voltage from the power supply unit 64B to perform a predetermined notification operation. As with the notification operation unit 62A of the first embodiment, the notification operation outputs a physical event that has occurred as a result of the notification operation to the outside as notification information.
[0063] The medical system 1B also includes an external device 200B that includes a detection unit 210B and a communication processing unit 220B, which detects the notification operation of the notification unit 60B and notifies the communication destination 300 that an abnormality has occurred in the continuous administration device 100B.
[0064] In the medical system 1B according to the second embodiment described above, the continuous administration device 100B is placed inside the living body while being filled with the substance X to be administered to the subject, and the external device 200B is placed in a position where a notification operation issued from the continuous administration device 100B outside the living body can be detected.
[0065] In the continuous administration device 100B, it is assumed that the movement of the stopper 40B has stopped due to some malfunction. In this case, when the internal pressure in the lumen 11B exceeds threshold B due to the stopper 40B's movement, the notification unit 60B causes the pressure exceeding threshold B to act on the blocking portion 63B, opening the liquid passage 62B. The power supply unit 64B generates a drive voltage by conducting the electrode 641B using the osmotic agent ZB that has flowed into the housing 61B from the opened liquid passage 62B as a conductor. The notification unit 60B drives the notification operation unit 65B with the drive voltage generated by the power supply unit 64B to perform a predetermined notification operation.
[0066] When notification information is output by the notification operation of the notification unit 60B, the external device 200B detects this notification information with the detection unit 210B and transmits an abnormality notification signal to the communication destination 300 (for example, a mobile terminal carried by the person to be notified) via the communication processing unit 220B. This allows the person to be notified to immediately confirm the abnormality of the continuous administration device 100B. Therefore, when a malfunction occurs in the continuous administration device 100B, the person to be notified can respond quickly even if they are in a location away from the patient in whom the continuous administration device 100B is placed.
[0067] Third Embodiment Next, a medical system 1C according to a third embodiment will be described with reference to FIGS. 7 to 9 as needed.
[0068] In addition, in the medical system 1C of the third embodiment, the components that have the same functions as those of the first and second embodiments described above are given the same symbols and detailed explanations are omitted, and the configurations, components, usage methods, etc. that are not specifically mentioned may be the same as those of the first and second embodiments described above.
[0069] 7 and 8, the medical system 1C is composed of a continuous administration device 100C and an external device 200C. The continuous administration device 100C also includes a main body 10C, a liquid-permeable section 20C, a pressing section 30C, a stopper 40C, a releasing section 50C, and a notifying section 60C.
[0070] As shown in Figures 7 and 8, the medical system 1C according to the third embodiment differs from the notification unit 60A of the first embodiment and the notification unit 60B of the second embodiment mainly in the configuration of the notification unit 60C. Furthermore, the pressing unit 30C is configured as an osmotic pressure engine, since it uses the pressing action caused by the inflow of the osmotic agent ZC as a driving source for the notification unit 60C to energize. When the internal pressure in the lumen 11C increases due to the stopper 40C stopping its movement, the osmotic agent ZC is prevented from expanding downstream by the stopper 40C, and flows upstream and into the notification unit 60C.
[0071] 8 or 9, the notification unit 60C includes a housing 61C serving as the main body, a liquid passage portion 62C provided in the housing 61C and having a liquid passage port 621C for the osmotic agent ZC flowing in from the pressing portion 30C, a conductor portion 63C that moves due to the osmotic agent ZC flowing in from the liquid passage portion 62C when the internal pressure in the lumen 11C exceeds a predetermined threshold C, a holding portion 64C that holds the conductor portion 63C on the liquid passage portion 62C side with a force weaker than the pressing force of the osmotic agent ZC, a power supply unit 65C that generates a driving voltage by conducting an electrode 651C due to the moved conductor portion 63C, and a notification operation unit 66C that performs a predetermined notification operation when the driving voltage is applied from the power supply unit 65C. The notification unit 60C is disposed on the tip side of the liquid permeable portion 20C so that the pressing force of the osmotic agent ZC from the pressing portion 30C acts on the liquid permeable portion 20C.
[0072] Like threshold value A and threshold value B, "threshold value C" can be set to a pressure value that is at least higher than the internal pressure in the lumen 11C when the stopper body 40C is operating normally, and lower than the pressure at which a burst of the administered substance X may occur due to an increase in internal pressure associated with the stopping of the movement of the stopper body 40C.
[0073] The housing 61C is made of a liquid-impermeable material to prevent short circuits in the power supply unit 65C and the notification operation unit 66C. The housing 61C is disposed on the tip side of the liquid permeable unit 20C so that the osmotic agent ZC can flow in.
[0074] The liquid passage portion 62C is formed with a liquid passage port 621C through which the osmotic agent ZC can pass, and is formed on the tip side of the housing 61C facing the pressing portion 30C so that the osmotic agent ZC can flow in. When the internal pressure in the lumen 11B exceeds the threshold C, that is, when an abnormality occurs in the continuous administration device 100B, the pressure due to the osmotic agent ZC flowing in from the liquid passage portion 62C increases, and the conductor portion 63C is driven upstream.
[0075] The liquid passage port 621C of the liquid passage portion 62C is always open, and allows not only the osmotic agent ZC but also the moisture that has permeated the liquid permeable portion 20C to flow in. However, the conductor portion 63C, which is disposed further distal than the power supply portion 65C and the notification operation portion 66C, prevents the osmotic agent ZC from penetrating upstream from the conductor portion 63C, so the space upstream of the conductor portion 63C within the housing 61C is sealed, and the power supply portion 65C and the notification operation portion 66C are not short-circuited.
[0076] The conductor portion 63C is made of a conductive material or a material containing a conductive material. The conductor portion 63C functions as a conductor for conducting the electrodes 651C of the power supply portion 65C. The conductor portion 63C can be made of, for example, a conductive metal plate.
[0077] The conductor portion 63C is held by the holding portion 64C so as to be movable along the axial direction of the main body portion 10C. When the internal pressure in the lumen 11C exceeds the threshold C, the conductor portion 63C is pressed upstream by the osmotic agent ZC flowing from the fluid passage portion 62C, and moves against the tensile force of the holding portion 64C. The conductor portion 63C is pushed and moved from its initial position to the conductive position (contact position with the electrode 651C) by the pressing action of the flowing osmotic agent ZC, and a portion (both ends) of the conductor portion 63C comes into contact with the electrode 651C. This enables the power supply unit 65C to generate electricity.
[0078] The retaining portion 64C retains the conductor portion 63C. The force of the retaining portion 64C to retain the conductor portion 63C is weaker (tensile force) than the pressing force of the osmotic agent ZC flowing in through the liquid passage port 621C of the liquid passage portion 62, and the conductor portion 63C is pulled and held toward the liquid passage portion 62C (downstream). In other words, the tensile force of the retaining portion 64C is set to a force that allows the conductor portion 63C to move from the initial position to the conducting position due to the pressing force of the osmotic agent ZC flowing in through the liquid passage port 621C when the internal pressure in the lumen 11C exceeds the threshold C. One end of the retaining portion 64C is connected to the liquid passage portion 62C, and the other end is connected to the conductor portion 63C. The retaining portion 64C can be configured with an elastic member (such as a torsion coil spring) that can retain the conductor portion 63C with a predetermined tensile force. 10, the holding portion 64C may be configured to be a compression spring that can expand and contract along the axial direction of the main body 10C, be disposed in the internal space of the housing 61C to hold the conductor 63C, and be configured to resist the pressure of the osmotic agent ZC. In this case, the force with which the holding portion 64C holds the conductor 63C is set to a force that can move the conductor 63C from the initial position to the conducting position when the internal pressure in the lumen 11C exceeds the threshold C and the pressing force of the osmotic agent ZC flowing in from the liquid passage port 621C.
[0079] The power supply unit 65C generates and supplies the drive voltage required to drive the notification operation unit 66C. The power supply unit 65C is composed of a battery 652C connected to a pair of electrodes 651C that are spaced apart so as to ensure an insulating distance within the housing 61C. The conductor portion 63C moves due to the inflow of the osmotic agent ZC from the liquid passage portion 62C and comes into contact with the electrode 651C, thereby establishing electrical conduction between the electrode 651C and the power supply unit 65C. The power supply unit 65C supplies (applies) the drive voltage generated by the conduction between the conductor portion 63C and the electrode 651C to the notification operation unit 66C. The type of battery constituting the power supply unit 65C is not particularly limited as long as it can be accommodated within the housing 61C and is capable of generating a drive voltage sufficient to drive the notification operation unit 66C.
[0080] The notification operation unit 66C is driven by a drive voltage from the power supply unit 65C to perform a predetermined notification operation. As with the notification operation unit 62A of the first embodiment and the notification operation unit 65B of the second embodiment, the notification operation outputs a physical event that has occurred as a result of the notification operation to the outside as notification information.
[0081] The medical system 1C also includes an external device 200C including a detection unit 210C and a communication processing unit 220C, which detects the notification operation of the notification unit 60C and notifies the communication destination 300 that an abnormality has occurred in the continuous administration device 100C.
[0082] In the medical system 1C according to the third embodiment described above, the continuous administration device 100C is placed inside the living body while being filled with the substance X to be administered to the subject, and the external device 200C is placed in a position where a notification operation issued from the continuous administration device 100C outside the living body can be detected.
[0083] In the continuous administration device 100C, it is assumed that the movement of the stopper 40C has stopped due to some malfunction. In this case, when the internal pressure in the lumen 11C exceeds the threshold C due to the stopper 40C's movement, the osmotic agent ZC flowing in from the fluid passage 62C presses the conductor 63C, causing the notification unit 60C to move upstream. The power supply unit 65C generates a drive voltage due to conduction between the conductor 63C that has moved upstream and the electrode 651C. The notification unit 60C drives the notification operation unit 66C with the drive voltage generated by the power supply unit 65C to perform a predetermined notification operation.
[0084] When notification information is output by the notification operation of the notification unit 60C, the external device 200C detects this notification information with the detection unit 210C and transmits an abnormality notification signal to the communication destination 300 (for example, a mobile terminal carried by the notification recipient) via the communication processing unit 220C. This allows the notification recipient to immediately confirm the abnormality of the continuous administration device 100C. Therefore, when a malfunction occurs in the continuous administration device 100C, the notification recipient can respond quickly even if they are in a location away from the patient in whom the continuous administration device 100C is placed.
[0085] [Effects] As described above, the continuous administration devices 100A to 100C according to the present embodiment comprise main bodies 10A to 10C having lumens 11A to 11C, stoppers 40A to 40C that are liquid-tight and slidable within the lumens 11A to 11C, pressing sections 30A to 30C that are arranged upstream of the stoppers 40A to 40C in the lumens 11A to 11C and press the stoppers 40A to 40C downstream, and pressing sections 30A to 30C that are housed downstream of the stoppers 40A to 40C in the lumens 11A to 11C and press the stoppers 40A to 40C downstream. and release sections 50A-50C that are disposed at the distal end of main body sections 10A-10C and release the substance X into the living body when pressed by stoppers 40A-40C, and are placed in the living body for sustained, gradual release of the substance X. The device is also provided with notification sections 60A-60C that perform a notification operation to notify the outside of an abnormality when the internal pressure of lumen 11A-11C exceeds a predetermined threshold value due to the stopper sections 40A-40C stopping movement.
[0086] This allows for notification of an abnormality to be sent to the outside when some malfunction occurs in the continuous administration device 100 placed in a living body, causing the movement of the stoppers 40A-40C to stop and the internal pressure in the lumens 11A-11C to exceed a predetermined threshold. Therefore, the person to be notified can immediately know that an abnormality has occurred in the continuous administration device 100. It also avoids the risk of losing the administration effect of the substance X due to cessation of sustained release and serious health damage due to a burst of the substance X. Therefore, even drugs that cause serious side effects when overdosed can be used as the substance X without concern, broadening the range of treatment options.
[0087] Furthermore, in the continuous administration device 100A according to this embodiment, the notification unit 60A may be configured to include a power supply unit 61A consisting of a piezoelectric element having a piezoelectric body 611A and a pair of electrodes 612A, which generates a drive voltage by the pressure applied when the internal pressure in the lumen 11A exceeds a threshold value A, and a notification operation unit 62A which performs a notification operation when the drive voltage is applied from the power supply unit 61A.
[0088] With this configuration, when the internal pressure in the lumen 11A of the continuous administration device 100A exceeds the threshold value A, the power supply unit 61A generates electricity to drive the notification operation unit 62A, thereby immediately notifying the person to be notified that an abnormality has occurred in the continuous administration device 100A.
[0089] Furthermore, the continuous administration device 100B according to this embodiment includes a liquid-permeable portion 20B arranged on the base end side of the main body portion 10B, and the pressing portion 30B is composed of an osmotic engine having an osmotic agent ZB that contains an electrolyte and swells with a liquid that permeates the liquid-permeable portion 20B. The notification portion 60B may include a liquid passage 62B for the osmotic agent ZB, a blocking portion 63B that normally blocks the liquid passage 62B and opens the liquid passage 62B when the internal pressure in the lumen 11B exceeds a threshold value B, a power supply portion 64B that has a pair of electrodes 641B and generates a drive voltage when the electrodes 641B are conductive due to the osmotic agent ZB that has flowed in from the liquid passage 62B, and a notification operation portion 65B that performs a notification operation when the drive voltage is applied from the power supply portion 64B.
[0090] With this configuration, when the internal pressure in the lumen 11B of the continuous administration device 100B exceeds the threshold value B, the osmotic agent ZB flowing in from the fluid passage 62B causes the power supply unit 64B to be energized and activate the notification operation unit 65B, thereby enabling the person to be notified to be immediately notified that an abnormality has occurred in the continuous administration device 100B.
[0091] Furthermore, the continuous administration device 100C according to this embodiment includes a liquid-permeable portion 20C arranged on the base end side of the main body portion 10C, and the pressing portion 30C is composed of an osmotic engine having an osmotic agent ZC that swells with the liquid that permeates the liquid-permeable portion 20C. The notification portion 60C may include a liquid-passing portion 62C having a liquid-passing port 621C for the osmotic agent ZC formed therein, a conductor portion 63C that moves upstream when pushed by the osmotic agent ZC flowing in from the liquid-passing portion 62C when the internal pressure in the lumen 11C exceeds a threshold C, a holding portion 64C that holds the conductor portion 63C on the liquid-passing portion 62C side with a force weaker than the pressing force caused by the inflow of the osmotic agent ZC, a power supply portion 65C that generates a drive voltage by conducting the moved conductor portion 63C with an electrode 651C, and a notification operation portion 66C that is driven by the drive voltage applied from the power supply portion 65C to perform a notification operation.
[0092] With this configuration, when the internal pressure in the lumen 11C of the continuous administration device 100C exceeds the threshold value C, the power supply unit 65C is electrically connected to the conductor unit 63C to activate the notification operation unit 62A, thereby immediately notifying the person to be notified that an abnormality has occurred in the continuous administration device 100C.
[0093] The medical systems 1A to 1C according to this embodiment comprise continuous administration devices 100A to 100C having any of the configurations described above, and external devices 200A to 200C that include detection units 210A to 210C that detect the notification operation of the notification units 60A to 60C and are placed outside the living body.
[0094] The notification information sent from the continuous administration devices 100A to 100C placed inside the living body can be detected by the external devices 200A to 200C placed outside the living body, so the person to be notified can immediately know that an abnormality has occurred in the continuous administration devices 100A to 100C.
[0095] In addition, in the medical systems 1A to 1C according to this embodiment, the external devices 200A to 200C may be configured to include communication processing units 220A to 220C that generate a notification signal indicating that the internal pressure of the lumen 11A to 11C has exceeded a predetermined threshold and transmit the notification signal to the communication destination 300.
[0096] This allows the notification recipient to notify the communication destination 300, such as a mobile terminal carried by the notification recipient, that an abnormality has occurred in the continuous administration device 100, and the notification recipient can immediately know that an abnormality has occurred in the continuous administration device 100A to 100C. Therefore, when a problem occurs in the continuous administration device 100A to 100C, the notification recipient can respond quickly even if they are in a location away from the patient in whom the continuous administration device 100A to 100C is placed.
[0097] This application is based on Japanese Patent Application No. 2022-049284, filed on March 25, 2022, the disclosure of which is incorporated herein by reference in its entirety.
[0098] 1A, 1B, 1C Medical system, 10A, 10B, 10C Main body portion 11A, 11B, 11C Lumen, 20A, 20B, 20C Liquid permeable portion, 30A, 30B, 30C Pressing portion, 40A, 40B, 40C Stopper body, 50A, 50B, 50C Release portion, 60A, 60B, 60C Notification portion, 61A, 64B, 65C Power supply portion, 62A, 65B, 66B Notification operation portion, 62B Liquid passage port, 62C Liquid passage portion (621C Liquid passage port), 63B Blocking portion, 63C Conductor portion, 64C Holding portion, 100A, 100B, 100C Continuous administration device, 200A, 200B, 200C External device, 210A, 210B, 210C: detection unit, 220A, 220B, 220C: communication processing unit, 611A: piezoelectric body, 612A: electrode, 641B, 651C: electrode, X: substance to be administered, Y1: first space, Y2: second space, ZA, ZB, ZC: osmotic agent.
Claims
1. A continuous administration device comprising: a main body having an inner cavity; a stopper body that can slide liquid-tightly within the inner cavity; a pressing section that is located upstream of the stopper body in the inner cavity and presses the stopper body downstream; an administration object that is contained downstream of the stopper body in the inner cavity and is released into the living body as the stopper body slides downstream; and a release section that is located at the tip of the main body and releases the administration object that has been pressed by the stopper body into the living body, wherein the continuous administration device is placed within the living body for the continuous, gradual release of the administration object, and further comprises a notification section that performs a notification operation to notify the outside of an abnormality when the internal pressure of the inner cavity exceeds a predetermined threshold value due to the stopper body stopping movement.
2. The continuous administration device of claim 1, wherein the notification unit includes: a power supply unit consisting of a piezoelectric element having a piezoelectric body and a pair of electrodes, and which generates a drive voltage from the pressure applied when the internal pressure in the lumen exceeds the threshold; and a notification operation unit which performs the notification operation when the drive voltage is applied from the power supply unit.
3. A continuous administration device as described in claim 1, comprising a liquid permeable portion disposed on the base end side of the main body portion, wherein the pressing portion is composed of an osmotic engine having an osmotic agent containing an electrolyte and that swells with a liquid that permeates the liquid permeable portion, and wherein the notification portion comprises: a liquid passage port for the osmotic agent; a blocking portion that normally blocks the liquid passage port and opens the liquid passage port when the internal pressure in the lumen exceeds the threshold value; a power supply portion having a pair of electrodes that conducts the electrodes when the osmotic agent flows in from the liquid passage port to generate a drive voltage; and a notification operation portion that performs the notification operation when the drive voltage is applied from the power supply portion.
4. A continuous administration device as described in claim 1, comprising: a liquid-permeable section disposed on the base end side of the main body section; the pressing section being composed of an osmotic engine having an osmotic agent that swells with liquid passing through the liquid-permeable section; and the notification section comprising: a liquid-passing section having a liquid-passing port formed therein for the osmotic agent; a conductor section that is pushed by the osmotic agent flowing in from the liquid-passing section and moves toward the base end side when the internal pressure in the lumen exceeds the threshold; a holding section that holds the conductor section on the liquid-passing section side with a force weaker than the pressing force caused by the inflow of the osmotic agent; a power supply section that generates a drive voltage by establishing conduction between the moved conductor section and an electrode; and a notification operation section that is driven by the drive voltage applied from the power supply section to perform the notification operation.
5. A medical system comprising: a continuous administration device according to any one of claims 1 to 4; and an external device disposed outside the living body, the external device including a detection unit that detects the notification operation of the notification unit.
6. The medical system according to claim 5, wherein the external device comprises a communication processing unit that generates and transmits to a communication destination a notification signal indicating that the internal pressure of the lumen has exceeded the threshold.
